García-Ruan K, González-Moreno J, Corona-Gutiérrez AA, Juárez-Leaños DI, Juárez-López JS, Rodríguez-Sánchez JL

Language: Spanish
References: 4
Page: 294-296
PDF size: 502.96 Kb.

ABSTRACT

Obstetric hemorrhage is the second cause of maternal death worldwide. From 2008 to 2010 in Guadalajara, Hospital Civil Juan I. Menchaca, obstetric hemorrhage was the first cause of maternal death. Activated recombinant factor VII is a hemostatic agent used in acute and excessive bleeding disorders in patients who suffer bleeding disorders and in those who do not. We present the case of a patient with massive obstetric hemorrhage not responding to conventional therapy, treated with rFVIIa in a third level hospital.

REFERENCES

1. Sobieszczyk S, Breborowicz GH. The use of recombinant factor VIIa. En: B-Lynch C, Keith LG, Lalonde AB, Karoshi M. Postpartum hemorrhage. 1a edición. Sapiens Publishing, 2006, pp. 233-54.

2. Hossain N, Shamsi T, Haider S, Soomro N, Khan NH, Memon GU, et al. Use of recombinant activated factor VII for massive postpartum hemorrhage. Acta Obstet Gynecol Scand 2007; 86 (10): 1200-6.

3. Bomken C, Mathai S, Biss T, Loughney A, Hanley J. Recombinant activated factor VII (rFVIIa) in the management of major obstetric haemorrhage: A case series and a Proposed Guideline for Use. Obstet Gynecol Int 2009.

4. Almagro-Vázquez D. Uso del rFVIIa como agente hemostático en trastornos hemorrágicos. Med Intensiva 2007; Vol 31 (No 6).